Proficio Capital Partners LLC Acquires New Holdings in Organon & Co. (NYSE:OGN)

Proficio Capital Partners LLC acquired a new stake in shares of Organon & Co. (NYSE:OGN) in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 26,393 shares of the company’s stock, valued at approximately $394,000.

A number of other institutional investors have also recently bought and sold shares of the company. Oppenheimer & Co. Inc. grew its holdings in Organon & Co. by 70.8% during the fourth quarter. Oppenheimer & Co. Inc. now owns 32,278 shares of the company’s stock valued at $482,000 after purchasing an additional 13,379 shares during the period. Fisher Funds Management LTD acquired a new position in shares of Organon & Co. in the fourth quarter valued at approximately $1,897,000. Deseret Mutual Benefit Administrators boosted its holdings in shares of Organon & Co. by 24.3% in the fourth quarter. Deseret Mutual Benefit Administrators now owns 6,256 shares of the company’s stock valued at $93,000 after buying an additional 1,222 shares during the period. Hussman Strategic Advisors Inc. acquired a new position in shares of Organon & Co. in the fourth quarter valued at approximately $2,820,000. Finally, Handelsbanken Fonder AB boosted its holdings in shares of Organon & Co. by 17.8% in the fourth quarter. Handelsbanken Fonder AB now owns 80,365 shares of the company’s stock valued at $1,199,000 after buying an additional 12,115 shares during the period. Institutional investors and hedge funds own 77.43% of the company’s stock.

Organon & Co. Price Performance

Shares of OGN opened at $15.72 on Tuesday. The firm has a market capitalization of $4.05 billion, a PE ratio of 4.72, a PEG ratio of 0.90 and a beta of 0.76. The company’s 50-day moving average is $15.44 and its 200-day moving average is $16.85. Organon & Co. has a fifty-two week low of $13.87 and a fifty-two week high of $23.10. The company has a debt-to-equity ratio of 17.73, a current ratio of 1.70 and a quick ratio of 1.21.

Organon & Co. (NYSE:OGN) last released its quarterly earnings results on Thursday, February 13th. The company reported $0.83 EPS for the quarter, missing the consensus estimate of $0.92 by ($0.09). Organon & Co. had a net margin of 13.49% and a return on equity of 431.62%. The business had revenue of $1.59 billion during the quarter, compared to analyst estimates of $1.57 billion. Equities analysts forecast that Organon & Co. will post 3.68 EPS for the current year.

Organon & Co. Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, March 13th. Investors of record on Monday, February 24th will be paid a $0.28 dividend. The ex-dividend date of this dividend is Monday, February 24th. This represents a $1.12 annualized dividend and a dividend yield of 7.13%. Organon & Co.’s dividend payout ratio (DPR) is presently 33.63%.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on OGN shares. Morgan Stanley reduced their price target on shares of Organon & Co. from $17.00 to $16.00 and set an “equal weight” rating for the company in a report on Friday, February 14th. TD Cowen upgraded shares of Organon & Co. to a “hold” rating in a report on Wednesday, January 15th. Finally, Barclays reduced their price target on shares of Organon & Co. from $26.00 to $24.00 and set an “overweight” rating for the company in a report on Friday, February 14th. One investment analyst has rated the stock with a sell rating, three have given a hold rating, two have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, Organon & Co. presently has a consensus rating of “Hold” and a consensus price target of $20.80.

About Organon & Co.

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.